Nursing impact on the CAR-T cell landscape

As we approach February 29, we are reminded of our last leap day, in 2016. Nearly 4 years ago, we treated our first patient with chimeric antigen receptor (CAR)-T cell therapy. We knew that we were using a therapy that was innovative, groundbreaking, and full of unknowns. How would the patient tolerate the infusion? Turns out this was reassuring. Would the patient have the toxic effects that we had read so much about? Yes. How would the patient respond? Would we have believed our future selves if they said that he is still in complete remission? We are not sure any of us could have predicted on our last leap day that, in just 4 years, we would build a robust CAR-T programme within our centre and become one of the highest accruing institutions for CAR-T cell therapy in the USA. The evolution of the nursing role over this period is a valuable story to share.